Potential ALX Oncology Holdings Inc. (NASDAQ:ALXO) shareholders may wish to note that the Chief Financial Officer, Peter Garcia, recently bought US$102k worth of stock, paying US$8.53 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 31%.

ALX Oncology Holdings Insider Transactions Over The Last Year

The Founder, Jaume Pons, made the biggest insider sale in the last 12 months. That single transaction was for US$108k worth of shares at a price of US$15.04 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$6.93. So it is hard to draw any strong conclusion from it.

In the last twelve months insiders purchased 16.40k shares for US$152k. But they sold 30.06k shares for US$338k. Over the last year we saw more insider selling of ALX Oncology Holdings shares, than buying. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Insider Ownership Of ALX Oncology Holdings

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data indicates that ALX Oncology Holdings insiders own about US$7.2m worth of shares (which is 2.0% of the company). We do generally prefer see higher levels of insider ownership.

So What Do The ALX Oncology Holdings Insider Transactions Indicate?

It's certainly positive to see the recent insider purchase. On the other hand the transaction history, over the last year, isn't so positive. Neither the level of insider ownership, nor the transactions over the last twelve months inspire us, but we think the recent buying is positive. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing ALX Oncology Holdings. To help with this, we've discovered 4 warning signs (1 is a bit unpleasant!) that you ought to be aware of before buying any shares in ALX Oncology Holdings.

Of course ALX Oncology Holdings may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com